WO2022019114A1 - 情報処理装置、情報処理方法、及び、プログラム - Google Patents

情報処理装置、情報処理方法、及び、プログラム Download PDF

Info

Publication number
WO2022019114A1
WO2022019114A1 PCT/JP2021/025617 JP2021025617W WO2022019114A1 WO 2022019114 A1 WO2022019114 A1 WO 2022019114A1 JP 2021025617 W JP2021025617 W JP 2021025617W WO 2022019114 A1 WO2022019114 A1 WO 2022019114A1
Authority
WO
WIPO (PCT)
Prior art keywords
health
herbal medicine
cultivation
crude drug
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/025617
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
真俊 舩橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sony Group Corp
Original Assignee
Sony Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sony Group Corp filed Critical Sony Group Corp
Priority to CN202180060974.7A priority Critical patent/CN116134464A/zh
Priority to US18/016,271 priority patent/US20230316431A1/en
Priority to JP2022537910A priority patent/JP7831291B2/ja
Publication of WO2022019114A1 publication Critical patent/WO2022019114A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
    • G06Q50/02—Agriculture; Fishing; Forestry; Mining
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B79/00—Methods for working soil
    • A01B79/005—Precision agriculture
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/04—Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/90—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Definitions

  • This technology relates to information processing equipment, information processing methods, and programs, and is particularly suitable for cultivating raw medicines, for example, in a diversity-enhancing cultivation method that promotes biodiversity and controls ecosystems to produce plants.
  • information processing devices, information processing methods, and programs that enable the provision of cultivation conditions.
  • tea cultivated by the Kyosei farming method (registered trademark) has more medicinal properties than tea cultivated by the conventional farming method.
  • tea is a kind of crude drug, and it is possible to obtain crude drugs rich in medicinal properties by cultivating crude drugs other than tea (plants from which they can be obtained) by the Kyosei Agricultural Method (registered trademark). Is expected.
  • the Kyosei farming method registered trademark
  • the Kyosei farming method can be said to be a diversity-enhancing cultivation method that promotes biodiversity and controls the ecosystem to produce plants, crude drugs are cultivated by the diversity-enhancing cultivation method. By doing so, it is expected that a crude drug rich in medicinal properties can be obtained.
  • This technology was made in view of such a situation, and makes it possible to provide appropriate cultivation conditions for cultivating crude drugs by a diversity-enhancing cultivation method.
  • the information processing device or program of the present technology associates the raw medicine with the cultivation conditions in which the raw medicine is cultivated by the diversity-enhancing cultivation method that promotes biodiversity and controls the ecosystem to produce plants.
  • This is an information processing device provided with a first specific unit for specifying cultivation conditions of a specific raw medicine, or a program for operating a computer as such an information processing device.
  • the information processing method of the present technology uses the first model that associates the crude drug with the cultivation conditions for cultivating the crude drug by the diversity-enhancing cultivation method that promotes biodiversity and controls the ecosystem to produce plants. It is an information processing method including specifying the cultivation conditions of a specific crude drug.
  • the crude drug is specified by using the first model that associates the crude drug with the cultivation conditions for cultivating the crude drug by the diversity-enhancing cultivation method that promotes biodiversity and controls the ecosystem to produce plants. Cultivation conditions for crude drugs are specified.
  • the information processing device may be an independent device or an internal block constituting one device.
  • the program can be provided by transmitting via a transmission medium or by recording on a recording medium.
  • FIG. 1 is a block diagram showing a configuration example of an embodiment of a Chinese herbal medicine industry support system to which this technology is applied.
  • the Chinese medicine industry support system is composed of a network 10, one or more sensor devices 11, one or more terminals 12, a server 13, and a database 14.
  • the Chinese herbal medicine industry support system analyzed various data (information) observed in the ecosystem including the fields where the crude drugs used for the production of Chinese herbs (medicinal plants from which they can be obtained) are cultivated, and the crude drugs cultivated in the fields. Collect big data including data, clinical data of people who took herbal medicines, and various other data.
  • the Chinese medicine industry support system obtains information for supporting the Chinese medicine industry using big data and provides it to users and the like.
  • the sensor device 11, the terminal 12, the server 13, and the database 14 are connected to the network 10 by wire or wirelessly so that they can communicate with each other.
  • the sensor device 11 has a sensor that senses various physical quantities and a communication function that transmits sensor data (data representing the sensed physical quantity) obtained as a result of the sensing by the sensor. Further, the sensor device 11 includes, if necessary, a position detection function for detecting the position of the sensor device 11 itself using, for example, GPS (Global Positioning System).
  • GPS Global Positioning System
  • the sensor device 11 senses a physical quantity by a sensor. Further, the sensor device 11 transmits the sensor data obtained by sensing by the communication function to the database 14 via the network 10. The sensor data is transmitted from the sensor device 11 to the database 14 together with the position information indicating the position of the sensor device 11 detected by the position detection function of the sensor device 11 as needed.
  • a sensor that senses electromagnetic waves including light such as a sensor (image sensor) that captures an image by sensing light, and a sensor (mic) that senses sound are adopted.
  • a sensor that senses physical quantities as information on various environments such as temperature, humidity, humidity, geomagnetism, atmospheric pressure, and odor can be adopted.
  • the sensor device 11 is installed in a field or the like where crude drugs are cultivated.
  • the sensor device 11 can be manually installed at a predetermined position.
  • the sensor device 11 can be installed by spraying the sensor device 11 while moving on an airplane, a ship, an automobile, or the like.
  • the sensor device 11 in the field (and its surroundings), for example, images of plants and insects, sounds of wind, voices of insects, sounds of rubbing leaves, air temperature, soil temperature, humidity, geomagnetism, etc. It is sensed. Then, in the sensor device 11, the sensor data obtained by sensing is transmitted to the database 14 via the network 10.
  • the terminal 12 is an information processing device used by a user who receives support from the Chinese medicine industry and a user who cooperates with the support of the Chinese medicine industry.
  • a portable terminal such as a smartphone, a tablet, or a wearable terminal can be adopted.
  • a notebook PC Personal Computer
  • a desktop PC and other devices having a communication function and an information input / output function (interface) for a user can be adopted.
  • the users who receive the support of the Chinese medicine industry and the users who cooperate in the support of the Chinese medicine industry are, for example, those who cultivate the crude drugs used for the production of the Chinese medicine (hereinafter, appropriately including corporations and organizations) and the preparation of the crude drugs.
  • the terminal 12 transmits various data to the database 14 via the network 10, for example, according to the operation of the user.
  • a person who cultivates crude drugs makes observations in various places in the environment where crude drugs are cultivated, such as a field, using the terminal 12, and the observation values representing the observation results are stored in a database via the network 10. Send to 14.
  • a person who takes a Chinese medicine or a person who is in charge of a clinical trial of a person who takes a Chinese medicine uses the terminal 12 to take the Chinese medicine, a lifestyle of a person who is taking the Chinese medicine, and a clinical trial.
  • Data (observed value) and the like are transmitted to the database 14 via the network 10.
  • the terminal 12 receives various data transmitted (provided) from the server 13 via the network 10, displays it as an image, or outputs it as voice to present it to the user.
  • the terminal 12 of a person who cultivates crude drugs can receive and display the cultivation conditions as a cultivation method for cultivating crude drugs by the Kyosei farming method (registered trademark) or the like from the server 13.
  • the terminal 12 of a person who prepares a crude drug to generate a herbal medicine can receive and display the blended amount of the crude drug used for producing the herbal medicine from the server 13.
  • the terminal 12 of the person taking the Chinese medicine or the person in charge of clinical trials and care of the person taking the Chinese medicine receives information on the Chinese medicine having the desired health effect from the server 13 from the server 13. Can be received and displayed.
  • the server 13 is an information processing device managed by a supporter who supports the Chinese herbal medicine industry.
  • the server 13 uses the data registered in the database 14 to provide information for supporting the herbal medicine industry, for example, cultivation conditions for cultivating a specific crude drug by the Kyosei farming method (registered trademark), and generation of a specific herbal medicine. Obtain information on the amount of crude drugs used in the market and Chinese herbal medicines that have specific health effects. Then, the server 13 provides the terminal 12 with information on such cultivation conditions, the blended amount, and the Chinese herbal medicine by transmitting the information to the terminal 12 via the network 10.
  • the database 14 registers (stores) data (information) transmitted from the terminal 12 via the network 10.
  • the server 13 may be one server or a set of a plurality of servers. Further, in the database 14, in addition to the database in which the data from the terminal 12 is registered, the data necessary for supporting the Chinese medicine industry, for example, the reference values of the active ingredient and the toxic component required for the Chinese medicine produced by the classical prescription, etc. Includes the database in which is registered.
  • FIG. 2 describes a procedure for exploring cultivation conditions for cultivating medicinal plants by the Kyosei Agricultural Method (registered trademark) and obtaining a production prescription for producing a Chinese herbal medicine that enhances health effects by using the crude drugs obtained from the medicinal plants. It is a figure.
  • Cultivation of medicinal plants by the cooperative farming method is carried out in various production areas, in a mixed or dense environment of various plants. Then, from medicinal plants, crude drugs having different various components can be obtained depending on the place of production, the time of year, and the like.
  • the cooperative farming method registered trademark
  • the problem is to search for a cultivation method (mixed dense cultivation method) (Problem 1).
  • various data that are cultivation conditions include, for example, meteorological data, GIS (Geographic Information System) data, and biodiversity data (information on organisms existing in the production area environment, etc.).
  • GIS Geographic Information System
  • GDPC Geographic Information System
  • the crude drugs obtained from medicinal plants have different components depending on the place of origin and the time of year. Then, the Chinese herbal medicine prescribed using such crude drugs must meet the quality standards for various active ingredients and toxic ingredients (poisonous substances), and how to prescribe such herbal medicine becomes a problem (Problem 2). ).
  • the problem is how to evaluate the health effects of Chinese herbs prescribed using crude drugs obtained from medicinal plants, that is, how to evaluate the health effects of Chinese herbs (Problem 3).
  • the health effects of Chinese herbs are evaluated by confirming the efficacy by bioassay and clinical effects for those who have taken Chinese herbs and those who have not. Efficacy confirmation by bioassay and clinical effect can be performed using in vitro test data, clinical data, epidemiological data, intestinal flora data, life log, and the like.
  • FIG. 3 is a diagram illustrating allelopathy.
  • allelopathy a chemical substance called allelochemical, which is a bioactive compound, is produced. Allerochemicals are primarily secondary metabolites. Secondary metabolites of plants have a pharmacological action (pharmacological effect). For example, phytochemicals (phytochemicals) produced and released by plants when insects bite them have pharmacological effects.
  • this technology presupposes that medicinal plants are cultivated by a diversity-enhancing cultivation method such as Kyosei farming method (registered trademark) instead of conventional farming method.
  • Diversity promotion cultivation method is a cultivation method that promotes biodiversity and controls the ecosystem to produce plants.
  • Kyosei Agricultural Method (registered trademark) is ecological by constructing and controlling an ecosystem utilizing the characteristics of plants under the constraints of no tillage, no fertilization, no pesticides, and no bringing in anything other than seeds and seedlings. It is an open-field crop cultivation method that produces useful plants in an optimized state (ecosystem optimization).
  • Kyosei farming method (registered trademark) is a kind of diversity promotion cultivation method.
  • Ecological optimization is a state in which multiple species achieve maximum growth while competing and coexisting to the extent possible under given environmental conditions.
  • Physiological optimization on which conventional farming relies, generally refers to changing environmental conditions in order to optimize the growth conditions of a single species.
  • Ecosystem functions are functions that regulate environmental conditions such as temperature, humidity, amount of sunshine, and organic matter and minerals in soil within a range where more organisms can live comfortably. As ecosystem function increases, it becomes possible to tolerate richer biodiversity, and therefore biodiversity and ecosystem function are in a synergistic relationship with each other.
  • FIG. 4 is a diagram showing an example of phytochemicals that increase due to interaction with insects.
  • the second column from the left represents the crude drug in which the fight chemical is increased by the interaction with the insect
  • the first column from the left represents the fight chemical as the active ingredient of the crude drug in the second column from the left
  • the third column from the left represents the Latin scientific name of the phytochemical in the first column from the left.
  • the active ingredient contained in the crude drug in the second column from the left is not limited to the one shown in the first column from the left, but there are a plurality of active ingredients.
  • the active ingredient of the crude drug shown in the first column from the left is a typical active ingredient.
  • FIG. 5 is a diagram showing a presentation example showing the interaction between organisms related to crude drugs.
  • the interaction between organisms related to crude drugs can be presented by a network (graph) consisting of a node representing an organism (species) and a link representing the interaction between organisms represented by the node.
  • a network that represents the interaction between organisms related to crude drugs is made by connecting a node that represents a crude drug (a medicinal plant from which it is obtained) and a node that represents an organism that interacts with the crude drug with a link that represents the interaction. It is composed.
  • the degree of interaction between organisms represented by nodes can be expressed by the length and thickness of links connecting the nodes representing organisms.
  • a network representing biological interactions related to crude drugs can be constructed using, for example, a data set provided by GloBI (Global Biotic Interactions).
  • FIG. 6 is a diagram showing the results of metabolome analysis between tea cultivated by the Kyosei farming method (registered trademark) and tea cultivated by the conventional farming method.
  • FIG. 6 shows the flavonoid content of tea cultivated by the Kyosei farming method (registered trademark) and the flavonoid content of tea cultivated by the conventional farming method.
  • the flavonoid content was calculated by identifying the chemical substances contained in the tea and integrating the intensity of the chemical substances identified as flavonoids. Flavonoids were identified at the chemical formula level (Chemical Formula Matched) and at the structural isomer level (Standard Matched).
  • the tea cultivated by the Kyosei farming method (registered trademark) has a higher flavonoid content than the tea cultivated by the conventional farming method.
  • tea cultivated by the Kyosei farming method expresses about 200 different components as compared with tea cultivated by the conventional farming method, and most of them are expressed. It has also been confirmed that it is registered as a medicinal ingredient.
  • tea is a kind of crude drug, according to the Kyosei Agricultural Method (registered trademark), it is possible to cultivate crude drugs with many medicinal ingredients (type and amount) by mixed dense cultivation that enhances the interaction between living organisms. It is expected that it can be done.
  • a Chinese herbal medicine that is a factor (health factor) that exerts a desired health effect is specified by using a flower model (a flower model of a health effect) described later.
  • the relationship between the Chinese herbal medicine identified as a factor that exerts the desired health effect and the desired health effect is fed back to the production (prescription) of the Chinese herbal medicine. Then, in the production (prescription) of Chinese herbal medicine, the objective function representing the change (degree) of the desired health effect with respect to the herbal medicine (herbal medicine contained in) obtained from the relationship between the Chinese medicine and the desired health effect is maximized (desired). The amount of crude drug compounded (which maximizes the health benefits of the drug) is calculated.
  • FIG. 7 is a diagram illustrating an outline of a flower model of crude drugs that associates crude drugs (medicinal plants from which crude drugs can be obtained) with cultivation conditions for cultivating crude drugs.
  • Each point on the drawing represents various crude drug species (Set of different species), and the ellipse represents the cultivation conditions for cultivating the crude drug.
  • the points within the range surrounded by the ellipse represent the crude drugs (seed) that are not cultivated (not cultivated) unless the cultivation conditions are represented by the ellipse.
  • the cultivation condition represented by the ellipse is a necessary condition for cultivating the crude drug represented by the points within the range surrounded by the ellipse.
  • cultivation parameters various parameters related to (presumed) cultivation of the crude drugs (hereinafter, also referred to as cultivation parameters) are used for various crude drugs. Big data is collected. Then, by learning big data of cultivation parameters for various crude drugs with AI (Artificial Intelligence), the cultivation parameters (types and values) that are significant for the cultivation of the crude drugs can be used as the cultivation conditions for the crude drugs. Be explored.
  • AI Artificial Intelligence
  • the relationship between the crude drug and the cultivation conditions of the crude drug is expressed by enclosing the point (including the area) representing the crude drug with an ellipse representing the cultivation conditions of the crude drug. Since this shape looks like a flower with an ellipse as a petal, in the present embodiment, the model represented by this shape is called a flower model.
  • the petals are a set of crude drugs (points representing) that the cultivation conditions represented by the petals (oval) are necessary for cultivation. You can also catch it. In this case, it can be said that the flower model is composed of petals representing a set of crude drugs required for cultivation under certain cultivation conditions.
  • a flower model of crude drugs that is, a flower model that associates crude drugs with the cultivation conditions of the crude drugs
  • petals (ovals imitating) that represent the cultivation parameters that can be the cultivation conditions are used. It can be set (added) as appropriate. If the cultivation parameters represented by the petals are significant cultivation conditions for the cultivation of crude drugs, the petals represented by the cultivation conditions are changed so that the cultivation conditions include points representing the crude drugs required for cultivation. On the other hand, if the cultivation parameters represented by the petals are not significant cultivation conditions, the petals disappear.
  • the cultivation parameters naturally required for the cultivation of all crude drugs for example, the presence or absence of air that is always present when cultivating crude drugs on the earth, cannot be considered (set) in the flower model. ..
  • the presence or absence and composition of air can be considered (set) as cultivation parameters.
  • an ecological niche of a desired crude drug such as a crude drug having a high active ingredient (a crude drug having an active ingredient of a predetermined value or more), that is, cultivation conditions as an appropriate cultivation method for cultivating the crude drug.
  • a desired crude drug such as a crude drug having a high active ingredient (a crude drug having an active ingredient of a predetermined value or more)
  • cultivation conditions as an appropriate cultivation method for cultivating the crude drug.
  • the flower model of the desired crude drug can be constructed, for example, by searching for the cultivation conditions represented by the petals including the points representing the desired crude drug by the gradient method.
  • cultivation parameters including at least parameters related to the Kyosei farming method are set as cultivation parameters that can be the cultivation conditions represented by petals. Then, the cultivation conditions (cultivation parameters) represented by the petals including the points representing the desired crude drug are searched by the gradient method, so that a flower model of the desired crude drug is constructed.
  • This flower model is a flower model that associates a desired crude drug with cultivation conditions for cultivating the desired crude drug by the Kyosei Agricultural Method (registered trademark). Then, in this technique, using such a flower model, the cultivation conditions (cultivation method) for cultivating the desired crude drug by the Kyosei farming method (registered trademark), for example, biodiversity and interaction that enhance the active ingredient of the crude drug. Cultivation conditions to promote the are specified.
  • the reproducibility of cultivating the desired crude drug by the Kyosei Agricultural Method registered trademark
  • the parameters related to the Kyosei farming method that is, the cultivation parameters that can be the cultivation conditions for cultivating the raw medicine by the Kyosei farming method (registered trademark), are, for example, the amount of local sunshine and the diversity of soil microorganisms. , There is information on the types of mixed plants, the height of ridges, the soil quality (water content of soil, good drainage, etc.).
  • information related to the conventional farming method for example, tillage, fertilization, use of pesticides, irrigation amount, etc., is set as cultivation parameters.
  • the range shown by Common species is the petals representing the conditions of Fields A, B, C as cultivation conditions, the conditions of Environment A, B, C, and the like. include. Therefore, as the cultivation conditions of crude drugs within the range indicated by Common species, the conditions of fields A, B, C, the conditions of environments A, B, C, etc. are all applied.
  • the field condition represents, for example, information on the field such as plants coexisting in the field.
  • the environmental condition represents, for example, information on the soil quality and the environment in which crude drugs such as sun and shade are cultivated.
  • the flower model of crude drugs in addition to specifying the cultivation conditions for cultivating the desired crude drugs, it is possible to cultivate in the current environment by setting petals representing the current environment (cultivation conditions) (suitable for cultivation). It is also possible to specify the crude drug. Thereby, for example, when the climate of the field changes, it is possible to predict a crude drug suitable for cultivation in the field after the change.
  • FIG. 8 is a diagram illustrating the construction of a flower model of crude drugs.
  • Crude drugs are cultivated under the Kyosei Agricultural Method (registered trademark) in various fields. Then, in the field, for example, the user uses the terminal 12 (FIG. 1) to cultivate information (information that can be a cultivation parameter) regarding the cultivation of crude drugs by the cooperative farming method (registered trademark), for example, soil, environment, and the like. Data on the yield and the like of products including crude drugs harvested in the field are collected and registered in the database 14. Sensor data obtained by sensing with the sensor device 11 installed in the field is also registered in the database 14.
  • the server 13 performs mathematical analysis using AI machine learning on the data registered in the database 14, and performs data optimization (lightening) and data assimilation. Further, on the server 13, a flower model of the desired crude drug specified by, for example, the operation of the terminal 12 by the user is constructed by using the significant data regarding the cultivation of the crude drug obtained as described above as the cultivation parameters and the like.
  • the cultivation conditions of the cooperative farming method (registered trademark) as a cultivation method for cultivating the desired crude drug are specified using the flower model of the desired crude drug, and the cultivation conditions are provided (transmitted) to the terminal 12.
  • the user implements (embodies) the cultivation conditions provided from the server 13 to the terminal 12 in the field, and cultivates the crude drug by the cooperative farming method (registered trademark).
  • the user collects cultivation information regarding the cultivation of crude drugs by the cooperative farming method (registered trademark) using the terminal 12 and registers the cultivation information in the database 14.
  • FIG. 9 is a diagram showing an example of constructing a flower model of a desired crude drug.
  • the flower model on the left is a flower model with petals (ovals) that represent the cultivation conditions as a cultivation method in the field when the cultivation of the desired crude drug is started in the field of Kyosei Agricultural Method (registered trademark). Shows.
  • the point representing the desired crude drug is out of the range shown by Common species where all the cultivation conditions in the field when starting the cultivation of the desired crude drug overlap.
  • the cultivation parameters unnecessary for the cultivation of the desired crude drug by the Kyosei Agricultural Method are discarded, and the significant cultivation parameters are searched for as the cultivation conditions of the desired crude drug.
  • a flower model composed of petals (ovals) containing points representing the desired herbal medicine is constructed.
  • the flower model on the right shows a flower model constructed by searching for cultivation conditions for cultivating the desired crude drug.
  • the conditions of field C, soil B, sunflower, dryness, and low ridges are the desired crude drugs. It has been discarded (disappeared) as an unnecessary cultivation parameter for cultivation.
  • the conditions of fields A and B among the cultivation conditions existing in the flower model on the left are soil A, and the conditions of field D not present in the flower model on the left and soil C. Being in the shade, being moist, and having high ridges are being sought as significant cultivation parameters for the cultivation of the desired crude drug.
  • FIG. 10 is a diagram showing another example of constructing a flower model of a desired crude drug.
  • the flower model on the left shows the desired crude drug and its desired crude drug constructed using data such as cultivation information collected when the crude drug is cultivated in a field of Kyosei Agricultural Method (registered trademark) in only one area. It shows a flower model that is associated with the cultivation conditions of crude drugs.
  • the cultivation parameters specific to that area affect all herbal medicines cultivated in the field in that area and are indicated by dotted circles. As such, it is represented by petals that include all the points that represent crude drugs cultivated in a field in one area.
  • the flower model on the right is constructed using data such as cultivation information collected when crude drugs are cultivated in the fields of the cooperative farming method (registered trademark) in multiple regions, which is one region plus one or more other regions.
  • the flower model which associates the desired crude drug with the cultivation condition of the desired crude drug is shown.
  • cultivation parameters specific to one region can affect the herbal medicines cultivated in the field in that region, but fields in other regions. It does not necessarily affect the herbal medicines cultivated in, but is represented by petals that include only the dots representing the herbal medicines that affect them, as indicated by the dotted ellipses.
  • FIG. 11 is a diagram showing an example of a manual for performing quality control for quality assurance of crude drugs.
  • GACP Good Agricultural and Collection Practice
  • GACP stipulates matters related to cultivation and collection methods of medicinal plants, processing and preparation such as drying and sorting, storage, transportation, and delivery to factories controlled by GMP.
  • FIG. 12 is a diagram showing an example of an HPLC (High Performance Liquid Chromatography) pattern of an alkaloid contained in Uncaria rhynchophylla, which is one of the crude drugs.
  • HPLC High Performance Liquid Chromatography
  • FIG. 12 shows the HPLC pattern of alkaloids contained in Uncaria rhynchophylla from different production areas.
  • the HPLC pattern of alkaloids contained in Uncaria rhynchophylla differs depending on the production area of Uncaria rhynchophylla, and is classified into patterns called R type, S type, SR type, SR2 type, etc.
  • the HPLC pattern of alkaloids contained in Uncaria rhynchophylla differs depending on the production area of Uncaria rhynchophylla, and therefore, the composition ratio of various components contained in Uncaria rhynchophylla also differs depending on the production area of Uncaria rhynchophylla.
  • FIG. 13 is a diagram showing an example of the component content of Uncaria rhynchophylla harvested in each field of each production area.
  • Uncaria rhynchophylla is used as an antispasmodic agent and analgesic agent, and contains alkaloids such as lincophyllin, isolinchophylin, corinoxane, hirsutine, and hirsutine as components. Those derived from Uncaria rhynchophylla contain almost no hirsutine, hirsutine, etc. As shown in FIG. 13, the component content of Uncaria rhynchophylla varies depending on the production area.
  • the component composition ratio and component content of Uncaria rhynchophylla differ depending on the production area. That is, the quality of Uncaria rhynchophylla differs depending on the production area. Therefore, even if the Uncaria rhynchophylla is handled according to the GACP as a manual described with reference to FIG. 11, it is difficult to obtain the Uncaria rhynchophylla having a desired quality, that is, a desired component (a desired type and amount of components).
  • Uncaria rhynchophylla When blending crude drugs containing Uncaria rhynchophylla to produce Uncaria rhynchophylla, in order to meet the standards for Uncaria rhynchophylla, Uncaria rhynchophylla with the desired ingredients, for example, by empirically blending Uncaria rhynchophylla for each production area. Prepared.
  • FIG. 14 is a diagram illustrating FIM (Functional Independence Measure) as an example of an index of health effect.
  • the crude drugs used for the production (prescription) of Chinese herbs especially the crude drugs cultivated by the Kyosei Agricultural Method (registered trademark) (obtained from medicinal plants), have various components that can exert pharmacological actions in addition to the active ingredients. It has been confirmed that (pharmacological component) is contained. It may be unclear whether each ingredient contained in crude drugs has physiological activity, and whether such an ingredient is effective (effective) must be confirmed for health effects such as actual clinical effects. I do not understand.
  • Health effect indicators are required for evaluation and prediction of health effects, such as the results of bioassays of various organ cells against Chinese herbs with various contents of active and toxic components. , Clinical data, epidemiological data can be adopted. In addition, FIM can be adopted as an index of health effect.
  • FIM is a measure of how much activities of daily living are possible on its own and is used to assess the patient's disability level and changes in the patient's condition in response to rehabilitation or medical intervention. FIM is described in, for example, J.M. Linacre et al. “The Structure and Stability Independent Measure.” Arch Phys Med Rahabil Vol75, February 1994.
  • FIM has 18 items of physical, psychological and social functions, that is, items “Eating” (Eating), “Grooming”, “Bathing”, “Clothing of the upper body” ( Dressing upper body), “Dressing lower body”, “Toileting”, “Bladder management”, “Bowel management”, “Bed, chair, wheelchair” (Bed, chair, wheelchair), “toilet” (Toilet), “bathing, shower” (Tub, shower), “walk / wheelchair” (Walk / wheelchair), “Stairs”, “Comprehension”, “Expression” It is a measure of “Expression”, “Social interaction", “Problem solving”, and “Memory”.
  • FIM is classified into the domain of motor functions and the domain of cognitive functions.
  • Motor function brain regions are classified into self-care, sphincter control, transfer, and classifications.
  • the items “feeding”, “dressing”, “bathing”, “upper body clothing”, “lower body clothing”, and “excretion” belong to self-management, and the items “bladder management” and “defecation management” belong to sphincter control. "Belongs.
  • the items “bed, chair, wheelchair”, “toilet”, “bathing, shower” belong to the movement, and the items “walking / wheelchair”, “stairs” belong to the movement ability.
  • the area of cognitive function is classified into the categories of communication and social cognition.
  • FIG. 15 is a diagram showing the experimental results of improvement of FIM as a health effect by ingestion of tea cultivated by Kyosei Agricultural Method (registered trademark).
  • the experiment targeted 117 people, including 45 people who consumed tea cultivated by Kyosei Farming (registered trademark), 42 people who consumed tea cultivated by conventional farming, and 30 people who consumed water. I went to.
  • FIG. 15 shows the total FIM (Total FIM) when tea cultivated by the Kyosei farming method (registered trademark) is ingested for 4 months, the FIM in the area of motor functions, and the cognitive functions. It shows the transition of FIM in the area of.
  • FIG. 15 in addition to the transition of FIM when ingesting tea cultivated by the Kyosei farming method (registered trademark) (Syneco), the transition of FIM when ingesting tea cultivated by the conventional farming method (Conv), and , The transition of FIM (Water) when water is ingested is also shown.
  • the threshold value is a significance level used in the test of the difference between the average values.
  • FIG. 16 is a diagram illustrating an outline of a flower model of health effects that associates health benefits with Chinese herbs.
  • each point on the drawing represents various health effects (indexes), and petals (ovals) represent factors that exert health effects (hereinafter, also referred to as health factors).
  • the dots in the petals represent the health effects caused by the health factors represented by the petals.
  • This technology collects big data of various health parameters related to (estimated) various health effects from various people. Then, by learning big data of health parameters for various health effects with AI, the health parameters that are significant for achieving the health effects (type, and if necessary, quantity (type). Value) Other) is searched for as a health factor of its health effect.
  • At least information on Chinese herbs is used as an essential health parameter in the flower model of health effects.
  • health effects are associated with Chinese herbs.
  • the information on the herbal medicine is, for example, the type and amount of the herbal medicine, the type and amount of the crude drug contained in the herbal medicine, the cultivation conditions, the type and amount of the components contained in the herbal medicine, and the like.
  • the relationship between the health effect and the Chinese medicine as a health factor that exerts the health effect is that the point (including the area) that expresses the health effect represents the Chinese medicine as a health factor that exerts the health effect. It is expressed in the form contained in the petals.
  • a flower model of health effects that is, a flower model that associates health effects with Chinese medicines that exert the health effects
  • An ellipse that imitates) can be set (added) as appropriate. If the health parameter represented by the petals is a significant health factor for the health effect, the petals represented by the health factor change to include points representing the health effect affected by the health factor. On the other hand, if the health parameters represented by the petals are not significant health factors, the petals disappear.
  • the subjective parameter is a parameter that is measured by a person and can be changed by the measurer, for example, a text created by a person (whether or not the content is based on an objective phenomenon) or the like.
  • FIM is a subjective parameter because it is measured clinically by a person such as a medical professional.
  • the objective parameter is a parameter measured by a machine, for example, an output value of a sensor or the like.
  • heart rate is influenced by subjective thinking, but is an objective parameter as long as it is measured by a heart rate monitor.
  • a biomarker measured by a machine is also an objective parameter.
  • the flower model of health effect for example, it is possible to identify (information) of a Chinese herbal medicine having a desired health effect and other health factors.
  • a flower model of a desired health effect can be constructed, for example, by searching for a health factor represented by a petal including a point representing the desired health effect by a gradient method.
  • a health parameter that can be a health factor represented by petals a health parameter that includes at least information on Chinese herbs is set. Then, a flower model of the desired health effect is constructed by searching for a health factor (a health parameter) represented by the petals including a point representing the desired health effect by the gradient method.
  • This flower model is a flower model that associates a desired health effect with a health factor that exerts the desired health effect. Then, in this technique, using such a flower model, Chinese herbs and lifestyles as health factors that exert a desired health effect are specified. By taking the Chinese herbal medicine specified by this technique, incorporating lifestyle habits, etc., it is possible to enhance the reproducibility of achieving the desired health effect.
  • Plant type represents information on the plant species as a crude drug (a medicinal plant from which it can be obtained) formulated in the Chinese herbal medicine to be ingested.
  • Methodabolome represents information on the component composition obtained by metabolome analysis of the crude drug (the medicinal plant from which it is obtained) formulated in the Chinese herbal medicine to be ingested.
  • Soil Microbiota represents information on the soil microbial flora of the soil in which the crude drug (the medicinal plant from which it is obtained) formulated in the Chinese herbal medicine to be ingested is cultivated.
  • Bioactivity / Bioavailability represents information on the bioactivity and bioavailability of the components of the Chinese medicine to be ingested (the function of the physiological activity when the components of the Chinese medicine are metabolized, etc.).
  • Teoxicity represents information on the toxic components of the Chinese herbal medicine to be ingested.
  • Genetics / Epigenetics represents genetic information (genetic information such as genetic disease risk).
  • “Lifestyle” represents lifestyle information (smoking habits, exercise habits, eating habits, etc.).
  • the flower model of health effects in addition to identifying health factors such as Chinese herbs and lifestyles that produce the desired health effects, the health effects that a person enjoys by setting petals that represent the health factors of any person. And predict the health benefits that a person will enjoy.
  • FIG. 17 is a diagram showing an example of health parameters other than Chinese herbs.
  • the following information can be adopted as health parameters other than Chinese herbs.
  • Immune system information such as inflammatory and allergies ⁇ Information on metabolome analysis using saliva and urine ⁇ Information on bacterial and viral flora such as intestinal and oral cavity and soil where ingested food is cultivated ⁇ Temperature Information on environmental conditions such as the condition of drinking water, ventilation, place of residence, travel history, etc. ⁇ Information on cultural conditions such as ethnicity, family structure, financial situation, etc. ⁇ Heavy metals contained in ingested foods, etc.
  • Toxicity information such as and mycotoxin
  • Genetic information such as genetic disease risk (Genetics, Epigenetics)
  • Information on lifestyle habits such as food, sleep, and exercise
  • Information on psychological conditions such as stress and how to spend leisure time
  • Information on external findings such as skin condition, musculoskeletal system, and complexion
  • FIG. 18 is a diagram showing an example of constructing a flower model with a desired health effect.
  • the flower model on the left shows a flower model with petals (ovals) representing the current health factors (health parameters) of the target person who wishes to enhance the desired health effect.
  • inflammatory marker values are the current health factors for the subject. Is (estimated).
  • the health parameters unnecessary for achieving the desired health effect are discarded, and the significant health parameters are searched for as the health factors of the desired health effect, and the desired health effect is obtained.
  • a flower model consisting of petals (ellipses) containing points to represent is constructed.
  • the flower model on the right shows a flower model constructed by searching for health factors with desired health effects.
  • FIG. 19 is a diagram illustrating the formulation of crude drugs that produce herbal medicines.
  • the components of crude drugs such as Uncaria rhynchophylla differ depending on the production area.
  • the ingredients of the crude drug for each lot differ depending on the place of origin of the lot.
  • the active ingredient of the Chinese herbal medicine produced by the blending is kept above the standard value of the active ingredient and is a toxic ingredient. However, it is kept below the standard value of toxic components.
  • the active ingredient and the toxic ingredient may be the same substance, and act on the living body as an active ingredient or a toxic ingredient depending on the concentration.
  • a flower model of the desired health effect is constructed using the results of bioassays and clinical effects of people who have taken the Chinese medicine, and the flower model is used to be a health factor that produces the desired health effect. (Information) is specified.
  • the active ingredient is above the standard value
  • the toxic component is below the standard value
  • the desired amount of the crude drug contained in the Chinese herbal medicine obtained from the relationship between the Chinese medicine and the desired health effect is desired.
  • the amount of herbal medicine that maximizes the objective function that represents the change in health effect is calculated using linear programming or nonlinear programming.
  • the calculation of the blended amount of the crude drug that maximizes the objective function is repeated. As a result, the accuracy of specifying the Chinese herbal medicine that is a factor that exerts the desired health effect and the accuracy of calculating the blended amount of the crude drug that maximizes the objective function representing the change in the desired health effect are increased.
  • the newly calculated amount of the herbal medicine will be the same as the amount of the previously calculated herbal medicine. If it can be regarded as (almost) the same, it is possible to construct a herbal medicine portfolio in which the newly calculated herbal medicine formulation amount is registered.
  • FIG. 20 uses a linear programming method to calculate the amount of herbal medicine that maximizes the objective function that represents the change in the desired health effect, with the active ingredient above the reference value and the toxic ingredient below the reference value. It is a figure which shows the example.
  • the active ingredient is placed above the reference value in a two-dimensional space (plane) centered on the mixed amounts x1 and x2 of the two crude drugs prepared when producing a Chinese herbal medicine that is a health factor that exerts a desired health effect.
  • a graph (shown by a solid line in the figure) showing the constraint conditions to set the toxic component to the reference value or less, and an objective function showing the change in the desired health effect with respect to the blended amount of the crude drug contained in the Chinese herbal medicine.
  • a graph (indicated by a dotted line in the figure) is drawn.
  • an objective function that expresses a change in a desired health effect in a feasible region that satisfies the constraint condition that the active ingredient is equal to or more than the reference value and the constraint condition that the toxic component is equal to or less than the reference value is obtained.
  • the compounded amount of the crude drug to be maximized for example, in FIG. 20, the compounded amount x1 and x2 of the two crude drugs are calculated.
  • the active ingredient is above the standard value.
  • the amount of the crude drug compounded, which has a toxic component below the reference value and maximizes the objective function representing the desired change in health effect, can be calculated using the linear programming method.
  • the objective function, the constraint condition, or both the objective function and the constraint condition become non-linear.
  • the non-linear programming method is used in consideration of non-linearity. It needs to be calculated using.
  • the preparation amount of the crude drug that maximizes the objective function representing the change in the desired health effect while the active ingredient is above the reference value and the toxic component is below the reference value is calculated using the nonlinear programming method. It is a figure which shows the example.
  • the active ingredient is set to a reference value or more in a three-dimensional space centered on the mixed amounts x, y, and z of the three crude drugs prepared when producing a Chinese herbal medicine that is a health factor that exerts a desired health effect.
  • a three-dimensional graph showing a constraint condition that the toxic component is below the reference value and a planar graph of an objective function showing a change in a desired health effect are drawn.
  • the three-dimensional graph showing the constraints and the planar graph of the objective function provide big data on the non-linear interaction between the components of the crude drug, etc., associated with the formulation of the crude drug when producing the herbal medicine and the digestion and absorption of the herbal medicine. It can be modeled using and calculated using the model obtained by the modeling.
  • the point of contact between the graph showing the constraint condition that the active ingredient is above the reference value and the toxic component is below the reference value and the graph of the objective function is the amount of the crude drug that maximizes the objective function. It is calculated.
  • the compounding amounts x, y, and z of the three crude drugs that maximize the objective function are calculated.
  • the point of contact between the graph representing the constraint condition and the graph of the objective function can be calculated by fitting the graph representing the constraint condition and the graph of the objective function, for example, with AI or the like.
  • FIG. 22 is a diagram showing crude drugs prepared in the production of Chinese herbal medicines classified as hot-temperature solution.
  • FIG. 22 the crude drugs prepared by the classic prescriptions of kakachi, maoto, and shoseiryuto, which are hot and cold solution agents, are shown in an elliptical shape.
  • a classical prescription is a prescription described in a Chinese classic.
  • the composition of crude drugs may differ depending on the place of origin, even if the names of the crude drugs are the same.
  • the cultivation conditions may change and the composition of the components may differ between the past and the present.
  • the health effect (efficacy) obtained by taking the Chinese herbal medicine produced by the formulation is that of the crude drug. It is presumed that the composition of the ingredients deviates from the health benefits originally expected of the herbal medicine.
  • FIG. 23 is a diagram showing an example of a production prescription.
  • the solid ellipse represents the formulation of the crude drug in the classical prescription
  • the dotted ellipse represents the formulation of the crude drug in the production formulation.
  • a production prescription for example, a method for formulating a crude drug that can exert the originally expected health effect on Kakachi produced by a classical prescription, that is, a production area or a production area prepared when Kakachi is produced by a classical prescription.
  • a classical prescription a method for formulating a crude drug that can exert the originally expected health effect on Kakachi produced by a classical prescription, that is, a production area or a production area prepared when Kakachi is produced by a classical prescription.
  • the amount of crude drugs cultivated in what production area or cultivation conditions is compounded. It is possible to construct information such as whether to do it (Reanalysis).
  • a more effective new herbal medicine is prepared by blending a herbal medicine (such as licorice) common to kakachi, maoto, and shoseiryuto, which are hot and cold resolving agents, and other herbal medicines. It is possible to construct a formulation method to produce Chinese herbal medicine as a hot and cold solution (Recombination).
  • a herbal medicine such as licorice
  • kakachi, maoto, and shoseiryuto which are hot and cold resolving agents, and other herbal medicines. It is possible to construct a formulation method to produce Chinese herbal medicine as a hot and cold solution (Recombination).
  • the herbal medicine can be discovered by, for example, using a flower model of a health effect to identify information on foods and drinks that are health factors that produce a desired health effect.
  • Kyosei farming method (registered trademark) (hereinafter, also referred to as the Kyosei farming method (registered trademark) tea)
  • the FIM as a health effect is improved. Therefore, Kyosei Agricultural Method (registered trademark) tea can be specified as a health factor having a specific health effect by using a flower model of health effect.
  • Kyosei Agricultural Method (registered trademark) tea is identified as a health factor that exerts a specific health effect, it can be said that Kyosei Agricultural Method (registered trademark) tea has a pharmacological action that contributes to a specific health effect. It can be recognized as a herbal medicine separate from tea cultivated by conventional farming methods.
  • FIG. 24 is a diagram illustrating a framework for dynamic real-time management of an ultra-diversity management system.
  • a super-diversity management system is implemented on the server 13.
  • the ultra-diversity management system is a system that dynamically manages data (information) about biodiversity and various other diversity in real time for quality control (quality control) of Chinese herbs and construction of production formulas. Is.
  • Data subject to dynamic real-time management include, for example, multi-ohmics data, Kyosei Agricultural Method (registered trademark).
  • Data on the biodiversity of the field bioassay and clinical test (clinical effect) data of people who took and did not take Chinese herbs and tea and other foods and drinks cultivated by Kyosei Agricultural Method (registered trademark).
  • FIG. 24 shows a framework for dynamic real-time management performed by an ultra-diversity management system.
  • Observations are performed by the sensor device 11 and the terminal 12, and the observed values obtained as a result of the observations (for example, the sensor data sensed by the sensor device 11 or the user operating the terminal 12).
  • the input text, the captured image, etc. are appropriately registered in the database 14.
  • multi-ohmics data, biodiversity data, bioassay and clinical test data, classical prescription data, and various other data are appropriately registered in the database 14.
  • the super-diversity management system implements multiple models, for example, various mathematical models (Models) such as machine learning models and statistical mathematical models. For a plurality of models, learning by AI is performed using the data registered in the database 14.
  • Models mathematical models
  • learning by AI is performed using the data registered in the database 14.
  • the super-diversity management system predicts the predicted values of various observed values by giving the data registered in the database 14 as an input (Input) to each model after training.
  • the super-diversity management system receives feedback (Feedback) of actual observed values and compares the actual observed values with the predicted values of the observed values.
  • the super-diversity management system judges the significance of the model and the data registered in the model and the database according to the comparison result between the actual observed value and the predicted value of the observed value, and according to the judgment result. , Models and data registered in the database are selected.
  • the model and the model and data registered in the model and the database are significant. Further, if the difference between the actual observed value and the predicted value of the observed value does not satisfy the condition such as the preset threshold value, it is determined that the model and the data registered in the model or the database are not significant.
  • the super-diversity management system deletes (discards) non-significant models among multiple models and leaves significant models (picked up and used).
  • the ultra-diversity management system deletes non-significant data from the data registered in the database 14 and leaves significant data.
  • the database 14 By registering the observed values in the database 14 and selecting the data registered in the database 14, the database 14 is adapted, that is, significant data is collected.
  • the server 13 uses the significant data collected in the database 14 to construct a flower model of crude drugs, a flower model of health effects, and a calculation of the amount of crude drugs to be prepared using a nonlinear programming method. Will be.
  • FIG. 25 is a block diagram showing a functional configuration example of the server 13.
  • the ultra-diversity management system 20 is mounted on the server 13.
  • the ultra-diversity management system 20 has a dynamic real-time management unit 21, a crude drug flower model construction unit 22, a health effect flower model construction unit 23, a compounding amount calculation unit 24, and a provision unit 25.
  • the dynamic real-time management unit 21 performs the dynamic real-time management described with reference to FIG. 24 and collects significant data in the database 14.
  • the crude drug flower model construction unit 22 functions as a first specific unit for specifying cultivation conditions for cultivating a specific crude drug (a medicinal plant from which the crude drug is obtained) by a cooperative farming method (registered trademark) using the crude drug flower model. ..
  • the raw medicine flower model construction unit 22 has significant data registered in the database 14 for the raw medicine flower model, for example, the yield of the raw medicine (the medicinal plant obtained) cultivated by the Kyosei farming method (registered trademark), and the yield of the raw medicine (the medicinal plant obtained).
  • the parameters included in the amount of sunshine in the field where the herb was cultivated the variety of soil microorganisms, the types of mixed plants, the height of the ridges, the soil quality, etc.
  • the parameters related to the Kyosei Agricultural Method registered trademark.
  • the crude drug flower model construction unit 22 uses the significant data registered in the database 14 for the crude drug flower model, and specifies, for example, by operating the terminal 12 from the set cultivation parameters.
  • a flower model of a specific crude drug is constructed by searching for the cultivation conditions represented by the petals including the points representing the crude drugs of the above, that is, the cultivation parameters (values) that are the cultivation conditions for cultivating the specific crude drug by the gradient method. ..
  • the crude drug flower model construction unit 22 uses the flower model of the specific crude drug to specify the cultivation parameters represented by the petals of the flower model as cultivation conditions with high reproducibility for cultivating the specific crude drug, and the provision unit 25.
  • the cultivation conditions supplied by the crude drug flower model construction unit 22 to the provision unit 25 include cultivation conditions for cultivating a specific crude drug by the Kyosei farming method (registered trademark).
  • the health effect flower model construction unit 23 functions as a second specific unit that identifies health factors such as Chinese herbs and lifestyles that exert a specific health effect by using the health effect flower model.
  • the health effect flower model construction unit 23 takes significant data registered in the database 14 for the health effect flower model, for example, a Chinese medicine containing a Chinese medicine whose compounded amount is calculated by the compounded amount calculation unit 24, or the Chinese drug. From the parameters included in the bioassay, clinical effect, FIM, lifestyle, etc. of the person who has done so, set the health parameters including at least the parameters related to the Chinese herbal medicine and, if necessary, the lifestyle.
  • the health effect flower model construction unit 23 uses significant data registered in the database 14 for the health effect flower model, and specifies, for example, by operating the terminal 12 from the set health parameters.
  • a flower model of a specific health effect is constructed by searching for the health factor represented by the petals including the point representing the specific health effect, that is, the health parameter that is the health factor that exerts the specific health effect by the gradient method. ..
  • the health effect flower model construction unit 23 identifies and provides the health parameters represented by the petals of the flower model as highly reproducible health factors that exert the specific health effect by using the flower model of the specific health effect.
  • Health effects The health factors supplied by the flower model building unit 23 to the providing unit 25 include (information on) Chinese herbs and, if necessary, lifestyle-related habits (information).
  • the health effect flower model construction unit 23 in specifying a herbal medicine or the like that is a health factor that exerts a specific health effect, is a herbal medicine (herbal medicine prepared by producing) obtained in the construction of a flower model with a specific health effect. The relationship between the health effect and the health effect is fed back (supplied) to the blended amount calculation unit 24.
  • the compounding amount calculation unit 24 is effective using significant data registered in the database 14, for example, as a result of metabolome analysis of each crude drug cultivated in each production area or each field, and reference values of active ingredients and toxic ingredients.
  • the blended amount of the crude drug used for producing the herbal medicine whose ingredient is equal to or more than the reference value and whose toxic component is equal to or less than the reference value is calculated and supplied to the providing unit 25.
  • the compounding amount calculation unit 24 uses the significant data registered in the database 14 to have a specific health effect on the compounded amount of the crude drug, in which the active ingredient is equal to or more than the standard value and the toxic component is equal to or less than the standard value.
  • the amount of the crude drug to be a classical prescription or a production prescription that maximizes the objective function representing the change in the above is calculated by a linear programming method or a non-linear programming method and supplied to the providing unit 25.
  • the objective function representing the desired change in health effect is obtained from the relationship between the Chinese herbal medicine and the health effect fed back from the health effect flower model construction unit 23.
  • the providing unit 25 is a cultivation condition including cultivation conditions related to the cooperative farming method (registered trademark) for cultivating a specific crude drug (medicinal plant obtained) from the crude drug flower model construction unit 22, and a health effect flower model construction unit.
  • the providing unit 25 displays the cultivation conditions, health factors, and the amount of crude drug compounded according to the operation of the server 13 by the supporter.
  • the providing unit 25 transmits and displays the cultivation conditions, health factors, and the blended amount of crude drugs to the terminal 12 according to the operation of the terminal 12 by the user.
  • the ultra-diversity management system 20 highly reproducible cultivation conditions for cultivating a specific crude drug desired by the user, highly reproducible Chinese herbal medicine and lifestyle that exert a specific health effect desired by the user, etc. It is possible to provide a blended amount of a crude drug that produces a highly reproducible herbal medicine that has a health factor and a specific health effect.
  • FIG. 26 is a diagram illustrating an outline of construction of a crude drug flower model of the crude drug flower model construction unit 22.
  • the crude drug flower model construction unit 22 uses the crude drug as the cultivation parameter c registered as significant data in the database 14, for example, the amount of sunshine and the yield of the crude drug d1 as the reproducibility for cultivating the crude drug d1.
  • a flower model of the crude drug d1 is constructed by searching for the amount of sunshine, which is the value (range) c1 as the cultivation parameter c that maximizes the reproducibility of cultivating d1, by the gradient method.
  • the ellipse (the ellipse shown by the solid line in the figure) surrounding the points representing the crude drug with high reproducibility of cultivation with respect to the amount of sunshine, which is the value c1 of the cultivation parameter c that maximizes the reproducibility of cultivating the crude drug d1, is the crude drug d1. It becomes one of the petals of the flower model of.
  • the petals represented by the ellipse surrounding the points representing the crude drug with high reproducibility of cultivation with respect to the amount of sunshine, which is the value c1 of the cultivation parameter c, include the crude drug d1 (the point representing).
  • the construction of the flower model of the health effect of the health effect flower model construction unit 23 is performed in the same manner as the construction of the flower model of the crude drug of the crude drug flower model construction unit 22.
  • FIG. 27 is a diagram illustrating an outline of calculation of the blended amount of the crude drug of the blended amount calculation unit 24.
  • the intake amount of the Chinese herbal medicine m1 as a health parameter that maximizes FIM as a specific health effect is searched by the gradient method, and a flower model of the specific health effect is constructed.
  • the relationship R between the Chinese herbal medicine m1 (intake amount) and the specific health effect is obtained, and this relationship R is the compounding amount calculation unit 24. Will be fed back to.
  • the compounding amount calculation unit 24 is within the range of the compounding amount a1 or more based on the active ingredient and the compounding amount a3 or less based on the toxic component as the compounding amount of the crude drug d1 used for producing the Chinese herbal medicine m1. Then, a non-linear programming of the amount a2 of the crude drug d1 that maximizes the objective function F that represents the change in the health effect obtained from the relationship R between the Chinese herbal medicine m1 fed back from the health effect flower model construction unit 23 and the specific health effect. Calculated by law.
  • FIG. 28 is a flowchart illustrating an example of specific processing of cultivation conditions performed by the crude drug flower model construction unit 22.
  • step S11 the crude drug flower model construction unit 22 sets, for example, the crude drug desired by the user to a specific crude drug in response to the operation of the terminal 12 by the user, and the process proceeds to step S12.
  • step S12 the crude drug flower model construction unit 22 cultivates the crude drug flower model including at least the parameters related to the Kyosei farming method (registered trademark) from the parameters included in the significant data registered in the database 14.
  • the parameter is set, and the process proceeds to step S13.
  • step S13 the crude drug flower model construction unit 22 cultivates a specific crude drug by the Kyosei farming method (registered trademark) from the set cultivation parameters using the significant data registered in the database 14 for the crude drug flower model.
  • the cultivation parameters that are the cultivation conditions to be carried out by the gradient method By searching for the cultivation parameters that are the cultivation conditions to be carried out by the gradient method, a flower model of a specific crude drug is constructed, and the process proceeds to step S14.
  • step S14 the crude drug flower model construction unit 22 specifies the cultivation conditions for cultivating the specific crude drug by the cooperative farming method (registered trademark) using the flower model of the specific crude drug, and supplies the specific crude drug to the providing unit 25. The process ends.
  • FIG. 29 is a flowchart illustrating an example of specific processing of health factors performed by the health effect flower model construction unit 23.
  • step S21 the health effect flower model building unit 23 sets the health effect desired by the user to a specific health effect according to, for example, the operation of the terminal 12 by the user, and the process proceeds to step S22.
  • step S22 the health effect flower model construction unit 23 sets health parameters including at least parameters related to Chinese herbs and lifestyle habits from the parameters included in the significant data registered in the database 14, and the process is performed. The process proceeds to step S23.
  • step S23 the health effect flower model construction unit 23 uses the significant data registered in the database 14 for the health effect flower model, and from the set health parameters, the health that is a health factor that exerts a specific health effect. By searching the parameters by the gradient method, a flower model of a specific health effect is constructed, and the process proceeds to step S24.
  • step S24 the health effect flower model building unit 23 identifies health factors including Chinese herbs and lifestyles that exert a specific health effect using the flower model of a specific health effect, and supplies the health factors to the providing unit 25. , The process ends.
  • FIG. 30 is a flowchart illustrating an example of a process of calculating the blended amount of the crude drug performed by the blended amount calculation unit 24.
  • step S31 the compounding amount calculation unit 24 acquires (receives) the relationship between the Chinese herbal medicine and the specific health effect from the health effect flower model construction unit 23, and the process proceeds to step S32.
  • step S32 the compounded amount calculation unit 24 calculates an objective function representing a change in the specific health effect with respect to the compounded amount of the crude drug contained in the herbal medicine from the relationship between the herbal medicine and the specific health effect, and the process is performed in step S33. Proceed to.
  • step S33 the compounding amount calculation unit 24 sets the reference value of the active ingredient and the reference value of the toxic component using the significant data registered in the database 14, and the process proceeds to step S34.
  • step S34 the compounding amount calculation unit 24 determines the compounding amount of the crude drug that maximizes the objective function that represents the change in a specific health effect while the active ingredient is equal to or more than the reference value and the toxic component is equal to or less than the reference value. It is calculated by a linear programming method or a non-linear programming method, supplied to the providing unit 25, and the processing is completed.
  • the series of processes of the terminal 12 and the server 13 described above can be performed by hardware or software.
  • a program constituting the software is installed in a computer as a terminal 12 or a server 13.
  • FIG. 31 is a block diagram showing a configuration example of an embodiment of a computer in which a program for executing a series of processes described above is installed, that is, a hardware configuration example of a terminal 12 and a server 13.
  • the program can be recorded in advance on the hard disk 905 or ROM 903 as a recording medium built in the computer.
  • the program can be stored (recorded) in the removable recording medium 911 driven by the drive 909.
  • a removable recording medium 911 can be provided as so-called package software.
  • examples of the removable recording medium 911 include a flexible disc, a CD-ROM (Compact Disc Read Only Memory), a MO (Magneto Optical) disc, a DVD (Digital Versatile Disc), a magnetic disc, and a semiconductor memory.
  • the program can be downloaded to the computer via a communication network or a broadcasting network and installed on the built-in hard disk 905. That is, for example, the program transfers wirelessly from a download site to a computer via an artificial satellite for digital satellite broadcasting, or transfers to a computer by wire via a network such as LAN (Local Area Network) or the Internet. be able to.
  • LAN Local Area Network
  • the computer has a built-in CPU (Central Processing Unit) 902, and the input / output interface 910 is connected to the CPU 902 via the bus 901.
  • CPU Central Processing Unit
  • the CPU 902 executes a program stored in the ROM (Read Only Memory) 903 accordingly. .. Alternatively, the CPU 902 loads the program stored in the hard disk 905 into the RAM (Random Access Memory) 904 and executes it.
  • ROM Read Only Memory
  • the CPU 902 performs the processing according to the above-mentioned flowchart or the processing performed according to the above-mentioned block diagram configuration. Then, the CPU 902 outputs the processing result from the output unit 906, transmits it from the communication unit 908, and records it on the hard disk 905, if necessary, via, for example, the input / output interface 910.
  • the input unit 907 is composed of a keyboard, a mouse, a microphone, and the like. Further, the output unit 906 is composed of an LCD (Liquid Crystal Display), a speaker, or the like.
  • LCD Liquid Crystal Display
  • the processes performed by the computer according to the program do not necessarily have to be performed in chronological order in the order described as the flowchart. That is, the processing performed by the computer according to the program includes processing executed in parallel or individually (for example, processing by parallel processing or processing by an object).
  • the program may be processed by one computer (processor) or may be distributed processed by a plurality of computers. Further, the program may be transferred to a distant computer and executed.
  • the system means a set of a plurality of components (devices, modules (parts), etc.), and it does not matter whether all the components are in the same housing. Therefore, a plurality of devices housed in separate housings and connected via a network, and a device in which a plurality of modules are housed in one housing are both systems. ..
  • this technology can take a cloud computing configuration in which one function is shared by multiple devices via a network and processed jointly.
  • each step described in the above flowchart can be executed by one device or shared by a plurality of devices.
  • the plurality of processes included in the one step can be executed by one device or shared by a plurality of devices.
  • ⁇ 1> Cultivation conditions for a specific herbal medicine using a first model that associates the herbal medicine with the cultivation conditions for cultivating the herbal medicine in a diversity-enhancing cultivation method that promotes biodiversity and controls the ecosystem to produce plants.
  • An information processing device including a first specific unit for specifying.
  • the first specific part searches for cultivation parameters that are cultivation conditions for cultivating the specific crude drug from the cultivation parameters related to the cultivation of crude drugs, including the parameters related to the diversity-enhancing cultivation method, by the gradient method.
  • the information processing apparatus according to ⁇ 1>, which constructs the first model.
  • the parameters related to the diversity-enhancing cultivation method include information on the amount of sunshine, the diversity of soil microorganisms, the types of mixed plants, the height of ridges, the amount of water in the soil, and the goodness of drainage of the soil.
  • the information processing apparatus according to ⁇ 2> which is 1 or more of the above.
  • ⁇ 4> Using a second model that correlates the health effect with the health factor including the herbal medicine that exerts the health effect, it further comprises a second specific part that identifies the health factor including the herbal medicine that exerts a specific health effect ⁇ 1. > To the information processing apparatus according to any one of ⁇ 3>.
  • the second specific part is to search for a health parameter that is a health factor that exerts the specific health effect from health parameters related to health, including parameters related to Chinese herbal medicine, by a gradient method.
  • the second specific part is to search for a health parameter that is a health factor that exerts the specific health effect from the health parameters including parameters related to Chinese herbs and lifestyles by a gradient method.
  • the information processing device according to ⁇ 6> for constructing a model.
  • ⁇ 8> Any of ⁇ 4> to ⁇ 7> further provided with a compounding amount calculation unit for calculating the compounding amount of the crude drug used for producing a herbal medicine in which the active ingredient is equal to or higher than the standard value of the active ingredient and the toxic component is equal to or less than the standard value of the toxic component.
  • Information processing device described in Crab. ⁇ 9> The compounding amount calculation unit has an objective function representing the change in the specific health effect with respect to the compounding amount of the crude drug, in which the active ingredient is equal to or more than the reference value of the active ingredient, the toxic component is equal to or less than the reference value of the toxic component.
  • the information processing apparatus wherein the amount of the crude drug to be mixed to be maximized is calculated by a linear programming method or a non-linear programming method.
  • the objective function is obtained from the relationship between the Chinese herbal medicine obtained in the construction of the second model and the health effect.
  • Information processing methods that include identifying.
  • ⁇ 12> Cultivation conditions for a specific herbal medicine using a first model that associates the herbal medicine with the cultivation conditions for cultivating the herbal medicine in a diversity-enhancing cultivation method that promotes biodiversity and controls the ecosystem to produce plants.
  • 11 sensor device 12 terminal, 13 server, 14 database, 20 ultra-diversity management system, 21 dynamic real-time management department, 22 raw medicine flower model construction department, 23 health effect flower model construction department, 24 compounding amount calculation department, 25 provision Department, 901 bus, 902 CPU, 903 ROM, 904 RAM, 905 hard disk, 906 output unit, 907 input unit, 908 communication unit, 909 drive, 910 input / output interface, 911 removable recording medium

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Business, Economics & Management (AREA)
  • Strategic Management (AREA)
  • Human Resources & Organizations (AREA)
  • Economics (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Marketing (AREA)
  • Tourism & Hospitality (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Soil Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Mining & Mineral Resources (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Quality & Reliability (AREA)
  • Development Economics (AREA)
  • Toxicology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Operations Research (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Game Theory and Decision Science (AREA)
PCT/JP2021/025617 2020-07-20 2021-07-07 情報処理装置、情報処理方法、及び、プログラム Ceased WO2022019114A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202180060974.7A CN116134464A (zh) 2020-07-20 2021-07-07 信息处理设备、信息处理方法和程序
US18/016,271 US20230316431A1 (en) 2020-07-20 2021-07-07 Information processing device, information processing method, and program
JP2022537910A JP7831291B2 (ja) 2020-07-20 2021-07-07 情報処理装置、情報処理方法、及び、プログラム

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020123762 2020-07-20
JP2020-123762 2020-07-20

Publications (1)

Publication Number Publication Date
WO2022019114A1 true WO2022019114A1 (ja) 2022-01-27

Family

ID=79729725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/025617 Ceased WO2022019114A1 (ja) 2020-07-20 2021-07-07 情報処理装置、情報処理方法、及び、プログラム

Country Status (4)

Country Link
US (1) US20230316431A1 (https=)
JP (1) JP7831291B2 (https=)
CN (1) CN116134464A (https=)
WO (1) WO2022019114A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7295591B1 (ja) 2022-07-07 2023-06-21 株式会社Agri Smile プログラム、情報処理方法、及び情報処理装置
EP4485333A4 (en) * 2022-02-21 2025-05-28 Sony Group Corporation INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD AND PROGRAM

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013172700A (ja) * 2012-02-27 2013-09-05 Ntt Facilities Inc 植物栽培システム、植物栽培方法及びプログラム
WO2014007109A1 (ja) * 2012-07-04 2014-01-09 ソニー株式会社 農作業支援装置および方法、プログラム、記録媒体、並びに農作業支援システム
WO2017104841A1 (ja) * 2015-12-16 2017-06-22 プランティオ株式会社 情報処理装置、情報処理方法、及びプログラム
WO2017199539A1 (ja) * 2016-05-18 2017-11-23 ソニー株式会社 情報処理装置、プログラム、及び情報処理方法
CN110134016A (zh) * 2019-05-20 2019-08-16 孙艺 一种基于人工智能的中草药栽培及药性鉴定标准制定系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258877B2 (en) * 2001-12-21 2007-08-21 Sunten Phytotech Co., Ltd. Herbal pharmaceutical composition for treatment of cardiovascular disease
US20040242454A1 (en) * 2003-06-02 2004-12-02 Gallant Stephen I. System and method for micro-dose, multiple drug therapy
CN102327297A (zh) * 2010-07-12 2012-01-25 尹享邑 同质中药材原料的制备方法
JP2016018224A (ja) * 2014-07-04 2016-02-01 サイバーワオン合同会社 健康状態予測診断利用サービスシステム
EP3193303B1 (en) * 2014-09-11 2024-01-31 Sony Group Corporation System and method for generating a relationship graphs
US20190385730A1 (en) * 2018-06-16 2019-12-19 Steven Franklin Baugh System and Method for Separately Managing Product Information and Customer Preferences and for Dispensing a Product from a Point of Sale Vending Machine
US11605047B2 (en) * 2018-11-01 2023-03-14 Centaur Analytics, Inc. Predictive post-harvest stored commodity management methods
US11692989B2 (en) * 2019-07-11 2023-07-04 Locus Solutions Ipco, Llc Use of soil and other environmental data to recommend customized agronomic programs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013172700A (ja) * 2012-02-27 2013-09-05 Ntt Facilities Inc 植物栽培システム、植物栽培方法及びプログラム
WO2014007109A1 (ja) * 2012-07-04 2014-01-09 ソニー株式会社 農作業支援装置および方法、プログラム、記録媒体、並びに農作業支援システム
WO2017104841A1 (ja) * 2015-12-16 2017-06-22 プランティオ株式会社 情報処理装置、情報処理方法、及びプログラム
WO2017199539A1 (ja) * 2016-05-18 2017-11-23 ソニー株式会社 情報処理装置、プログラム、及び情報処理方法
CN110134016A (zh) * 2019-05-20 2019-08-16 孙艺 一种基于人工智能的中草药栽培及药性鉴定标准制定系统

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUNABASHI, MASATOSHI: "Strengthening the power of the agroecosystem heading to the information industry", NIKKEI ELECTRONICS, no. 1165, 1 March 2016 (2016-03-01), JP , pages 97 - 109, XP009533566, ISSN: 0385-1680 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4485333A4 (en) * 2022-02-21 2025-05-28 Sony Group Corporation INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD AND PROGRAM
JP7295591B1 (ja) 2022-07-07 2023-06-21 株式会社Agri Smile プログラム、情報処理方法、及び情報処理装置
WO2024010058A1 (ja) * 2022-07-07 2024-01-11 株式会社Agri Smile 情報処理方法、記録媒体及び情報処理装置
JP2024007958A (ja) * 2022-07-07 2024-01-19 株式会社Agri Smile プログラム、情報処理方法、及び情報処理装置

Also Published As

Publication number Publication date
JPWO2022019114A1 (https=) 2022-01-27
JP7831291B2 (ja) 2026-03-17
US20230316431A1 (en) 2023-10-05
CN116134464A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
Campbell et al. Getting more power from your flowers: Multi-functional flower strips enhance pollinators and pest control agents in apple orchards
Franco et al. Ecological intensification of food production by integrating forages
KR20190046841A (ko) 정보 처리 장치 및 정보 처리 시스템
Moradi et al. Anthropic Effects on the Biodiversity of the Habitats of Ferula gummosa
An Mathematical modelling of dose-response relationship (hormesis) in allelopathy and its application
JP7831291B2 (ja) 情報処理装置、情報処理方法、及び、プログラム
Gebrehiwot et al. Weed-competitive ability of teff (Eragrostis tef (Zucc.) Trotter) varieties
Adeux et al. Low-input maize-based cropping systems implementing IWM match conventional maize monoculture productivity and weed control
Macusi et al. Indigenous knowledge systems and practices (IKSPs), livelihood resources and aspirations of the Matigsalog and Ata tribes
Betti et al. Bee++: An object-oriented, agent-based simulator for honey bee colonies
Pinke et al. Weed composition in hungarian phacelia (Phacelia tanacetifolia benth.) seed production: could tine harrow take over chemical management?
Yang et al. The floral biology, breeding system and pollination efficiency of Schima superba Gardn. et Champ.(Theaceae)
Pomatto et al. Evaluation of different combinations of ornamental perennials for sustainable management in urban greening
Kowalska et al. Effect of plant seed mixture on overwintering and floristic attractiveness of the flower strip in Western Poland
Boff et al. Homeopathy applied to agriculture: theoretical and practical considerations with examples from Brazil
Morrison et al. The attractiveness of five common Mediterranean weeds to pollinators
Mocelin et al. Grazing management targets for tangolagrass pastures
Cruces et al. Advances in the integrated pest management of quinoa (Chenopodium quinoa Willd.): a global perspective
Rogers et al. Behavior in free-living American black bear dens: parturition, maternal care, and cub behavior
Luna et al. Is pasture cropping a valid weed management tool?
Hyder et al. Enhancing Coccinella beetle biological pest control via a floral approach in cucumber greenhouse
Paolino et al. May the Extensive Farming System of Small Ruminants Be Smart?
Mantilla Afanador et al. Novel lactone-based insecticides and Drosophila suzukii management: Synthesis, potential action mechanisms and selectivity for non-target parasitoids
Yıldız et al. Reproductive biology of Fritillaria aurea Schott (Liliaceae), a rare species endemic to Turkey
JP6686887B2 (ja) 情報処理装置、情報処理方法、およびプログラム

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21845541

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022537910

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21845541

Country of ref document: EP

Kind code of ref document: A1